![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25393-25397, September 3, 1999
From the University Laboratory of Physiology, Parks Road, Oxford
OX1 3PT, United Kingdom
Vanadate is used as a tool to trap magnesium
nucleotides in the catalytic site of ATPases. However, it has also been
reported to activate ATP-sensitive potassium (KATP)
channels in the absence of nucleotides. KATP channels
comprise Kir6.2 and sulfonylurea receptor subunits (SUR1 in pancreatic
beta cells, SUR2A in cardiac and skeletal muscle, and SUR2B in smooth
muscle). We explored the effect of vanadate (2 mM), in the
absence and presence of magnesium nucleotides, on different types of
cloned KATP channels expressed in Xenopus
oocytes. Currents were recorded from inside-out patches. Vanadate
inhibited Kir6.2/SUR1 currents by ~50% but rapidly activated
Kir6.2/SUR2A (~4-fold) and Kir6.2/SUR2B (~2-fold) currents. Mutations in SUR that abolish channel activation by magnesium nucleotides did not prevent the effects of vanadate. Studies with chimeric SUR indicate that the first six transmembrane domains account
for the difference in both the kinetics and the vanadate response of
Kir6.2/SUR1 and Kir6.2/SUR2A. Boiling the vanadate solution, which
removes the decavanadate polymers, largely abolished both stimulatory
and inhibitory actions of vanadate. Our results demonstrate that
decavanadate modulates KATP channel activity via the SUR
subunit, that this modulation varies with the type of SUR, that it
differs from that produced by magnesium nucleotides, and that it
involves transmembrane domains 1-6 of SUR.
ATP-sensitive potassium
(KATP)1 channels
are found in a variety of tissues where they couple changes in cellular
metabolism to electrical activity and potassium fluxes (1-3).
Molecular cloning of these channels has revealed that they consist of
two distinct types of subunit (a pore-forming subunit (Kir6.2) and a
sulfonylurea receptor subunit (SUR1 in pancreatic beta cells, SUR2A in
cardiac and skeletal muscle, and SUR2B in smooth muscle)) that
associate in a 4:4 stoichiometry to form an octameric KATP channel. (4-12). The sulfonylurea receptor subunit belongs to the
ATP-binding cassette (ABC) transporter family and is characterized by
multiple transmembrane domains and two large cytosolic loops that
contain consensus sequences for nucleotide binding and hydrolysis (4,
13). Like the nucleotide-binding domains (NBD) of other ABC
transporters, those of the sulfonylurea receptor each possess a Walker
A and a Walker B motif.
Adenine nucleotides exert both stimulatory and inhibitory effects on
KATP channel activity that are mediated by separate
subunits. Thus, interaction of ATP with Kir6.2 causes the channel to
close, whereas interaction of MgADP or MgATP with the NBDs of SUR
enhances KATP channel activity (14-17). A number of
studies have directly demonstrated ATP binding and hydrolysis by the
nucleotide-binding domains of several members of the ABC transporter
family, including P-glycoprotein (MDR; Ref. 18), the multidrug
resistance-like protein (MRP; Ref. 19), the cystic fibrosis gene
product (CFTR; Ref. 20), and the bacterial maltose transporter
(21).
Vanadate is routinely used as a tool to trap magnesium nucleotides in
the catalytic site of ATPases. ADP is trapped by vanadate both as a
result of ATP hydrolysis and also when it is added directly to the
solution (22). This is likely to be because orthovanadate acts as an
analogue of phosphate. Among eukaryotic ABC transporters, vanadate
trapping has been demonstrated for both MDR (18) and MRP (19).
Photoaffinity labeling experiments with 8-azido-[32P]ATP
have revealed that ATP binds with high affinity to NBD1 of SUR1
and that MgADP binds to NBD2 (23). Unlike other ABC transporters,
however, nucleotide binding to SUR1 is not enhanced by vanadate
(23).
The effects of vanadate on KATP channel currents are
variable. It has been reported to enhance the activity of
KATP channels in skeletal muscle (24) and in ventricular
myocytes (25), but it had no effect on the cloned KATP
channel Kir6.2/SUR1 in the presence of magnesium nucleotides (16). One
explanation for these disparate findings is that different types of
KATP channel exhibit different sensitivities to vanadate.
Another reason may be that vanadate interacts with a third protein, not
present in the heterologous expression system, to modulate
KATP channel activity. A third possibility is that, because
vanadate exists in solution in a number of different polymeric forms
(e.g. orthovanadate and decavanadate), the concentration of
the different vanadate complexes might vary in the experimental
solutions used by different investigators.
In this paper, we examine the effects of orthovanadate and decavanadate
on the activity of cloned KATP channels containing different types of SUR subunit, heterologously expressed in
Xenopus oocytes. We show that the major effects of vanadate
on KATP channel activity are mediated via the sulfonylurea
receptor subunit, with different SURs producing different modulatory
effects. We further demonstrate that the interaction of vanadate with
SUR is not mediated via the nucleotide-binding domains and that the
first six transmembrane domains are required for activation of SUR2 by
vanadate. This region also determines the different kinetics of
Kir6.2/SUR1 and Kir6.2/SUR2 channels.
Molecular Biology--
Mouse Kir6.2 (GenBankTM
accession number D50581, Refs. 5 and 11), rat SUR1
(GenBankTM accession number L40624, Ref. 4; provided by
Dr. G. Bell, University of Chicago), rat SUR2A (GenBankTM
accession number D83598, Ref. 6; provided by Dr. S. Seino, Chiba
University School of Medicine), and rat SUR2B (GenBankTM
accession number AF019628, Ref. 8) were subcloned into the pBF
expression vector that provides the 5'- and 3'-untranslated regions of
the Xenopus Oocyte Handling--
Female Xenopus laevis were
anesthetized with MS222 (2 g/liter added to the water). One ovary was
removed via a minilaparotomy, the incision was sutured, and the animal
was allowed to recover. Once the wound had completely healed, the
second ovary was removed in a similar operation, and the animal was
then killed by decapitation while under anesthesia. Immature stage V-VI
Xenopus oocytes were incubated for 60 min with 0.1 mg/ml
collagenase (type V, Sigma) and then manually defolliculated. In most
experiments, oocytes were injected with ~2 ng of mRNA encoding
SUR (either the wild-type or mutant form of SUR1, SUR2A, or SUR2B) and
~0.04 ng of Kir6.2 mRNA. In some experiments, oocytes were
injected with 2 ng of mRNA encoding Kir6.2 Electrophysiology--
Patch pipettes were pulled from
thick-walled glass and had resistances of 250-500 kilo-ohms when
filled with pipette solution. Macroscopic currents were recorded from
giant inside-out patches using an EPC-7 patch clamp amplifier (List
Electronik, Darmstadt, Germany) at 20-24 °C (26). The holding
potential was 0 mV, and currents were evoked by repetitive 3-s voltage
ramps from
The pipette solution contained (in mM): KCl, 140;
MgCl2, 1.2 ; CaCl2, 2.6; and HEPES, 10 (pH 7.4 with KOH). The internal (bath) solution contained (in mM):
KCl, 135; MgCl2, 5; KOH, 5; EGTA, 1; HEPES, 10 (pH 7.2 with
KOH); and nucleotides as indicated. Sodium vanadate
(Na3VO4, Sigma) was added to the solution at a concentration of 2 mM, and the pH was adjusted to 7.2 with
KOH. At concentrations higher than ~100 µM, vanadate
exists in solution in a number of polymeric forms (27). At room
temperature and pH 7.2, the vanadate monomer (orthovanadate) coexists
in equilibrium with small amounts of divanadate and tetravanadate (28).
A small amount of decavanadate is also generated immediately after pH readjustment, and its presence is indicated by the characteristic yellow color of the solution (27). Because decavanadate is not stable
at pH 7.2 and slowly decomposes with time (27), solutions were made up
just before starting the experiment and were only used for 1-2 h. To
prevent chelation of vanadate species by EGTA, we used a low
concentration of the chelator (1 mM) and increased the
Mg2+ concentration to 5 mM. Boiling the
vanadate solution for ~30 min permanently removes decavanadate, which
can be visualized by a change of color from yellow (decavanadate) to
colorless (27). Boiled solutions contain mostly orthovanadate, although
bivanadate and tetravanadate may also be present (28, 29). In this
paper, we refer to the unboiled solution as "vanadate solution" and
the boiled solution as "decavanadate-free vanadate solution."
Solutions containing vanadate were made up fresh each day, and the pH
was readjusted after addition of Na3VO4 with
HCl. For decavanadate-free solutions, ADP was added after boiling.
Rapid exchange of solutions was achieved using a rapid solution changer
(RSC-2000, Biologic, Claix, France).
Data Analysis--
The slope conductance was measured by fitting
a straight line to the current-voltage relation between
All data are given as mean ± S.E. The symbols in the
figures indicate the mean, and the vertical bars represent
one S.E. (where this is larger than the symbol). Statistical
significance was tested by Student's t test. The
concentration dependence of the activatory and inhibitory effects of
vanadate on channel activity were fitted according to Equations 1 and
2,
Effects of Vanadate on Channel Activity--
Fig.
1, A and B, shows
that intracellular application of 2 mM sodium vanadate
(Na3VO4) produced a marked stimulation of
Kir6.2/SUR2A currents and a somewhat smaller increase in Kir6.2/SUR2B
currents; the mean increase in the conductance was 454 ± 127%
(n = 7) for Kir6.2/SUR2A and 174 ± 24%
(n = 8) for Kir6.2/SUR2B (Table
I). In contrast, vanadate blocked
Kir6.2/SUR1 currents (Fig. 1C). The extent of this block
varied between oocyte preparations, with a mean inhibition of 55 ± 9% (n = 18). The block was slow and only partially
reversible. In some experiments (Fig. 1C,
bottom), removal of vanadate caused an initial decrease and
then an increase in current, suggesting that the ion might exert more
than one effect on Kir6.2/SUR1.
When Kir6.2 Effects of Decavanadate-free Solution on Channel Activity--
We
next explored whether the effects of vanadate were mediated by the
decavanadate species. To address this question, we boiled the vanadate
solution to remove decavanadate. As shown in Table I, the
decavanadate-free vanadate solution was without marked effect on the
amplitude of Kir6.2 Concentration Dependence of Vanadate-induced Effects--
To
compare the sensitivity of cloned and native KATP channels,
we measured the concentration-response curves for the effects of
vanadate on Kir6.2/SUR2A and Kir6.2/SUR1 currents (Fig.
2). The EC50 for vanadate
activation of Kir6.2/SUR2A currents was 0.59 ± 0.03 mM, with a Hill coefficient of 1.8 ± 0.2 and maximum activation of 3.25 ± 0.06 (n = 5). The
EC50 was slightly lower than the value (1.5 mM)
reported by Neumcke and Weik (24) for native cardiac KATP
channels but similar to that obtained by Nakashima et al.
(25) in the presence of 300 µM ATP (0.5 mM).
The inhibitory effect of vanadate on Kir6.2/SUR1 had an
EC50 of 0.28 ± 0.02 mM and a Hill
coefficient of 2.9 ± 0.5 (n = 5). Approximately
30% of the current was unaffected by vanadate. That the Hill
coefficients for both activation and inhibition of KATP
currents were larger than one suggests that the cooperative action of
more than one vanadate molecule is involved in these effects. The fact
that vanadate was without effect at a concentration of 0.1 mM supports the idea that the effects are mediated by
vanadate polymers, which are only generated in solutions containing
>0.1 mM vanadate (27).
Effects of Decavanadate-free Solutions on the Response to
MgADP--
Vanadate-trapping effects are generally assigned to the
orthovanadate species (30, 31). Magnesium nucleotides enhance KATP channel activity, with the most dramatic effects being
caused by MgADP. Therefore, we examined the effect of decavanadate-free solution on the ability of MgADP to enhance the activity of the KATP channel. If orthovanadate causes nucleotide trapping,
we would expect it to influence the stimulatory effect of MgADP. In
control solution, 3 µM and 100 µM MgADP
increased Kir6.2/SUR1 currents by ~28 and ~700%, respectively
(Fig. 3 and Table
II). There was no change in the effect of
MgADP when the nucleotide was applied in the presence of
decavanadate-free vanadate solution. Shyng et al. (16) have
also reported that vanadate has no effect on the potentiatory action of
MgADP on Kir6.2/SUR1 currents.
Effects of Mutations in SUR on Decavanadate Action--
Our
results indicate that the effects of decavanadate are mediated by the
sulfonylurea receptor and not by the Kir6.2 subunit. The stimulatory
effects of MgADP and of potassium-channel openers such as diazoxide are
impaired by mutations in the NBDs of SUR (14-16). To determine whether
this is also the case for decavanadate, we examined the effects of
mutations that are known to disrupt the activation of Kir6.2/SUR1
currents by both MgADP and diazoxide (14, 16); thus we changed one or
both lysines in the Walker motifs of NBD1 and NBD2 to alanine or
methionine. The effect of vanadate solution on KATP
channels containing SUR1, SUR2A, or SUR2B carrying these mutations was
unchanged, indicating that the mechanism of vanadate activation is
distinct from that of MgADP (Table I).
Effects of Decavanadate on SUR Chimeras--
To identify regions
of SUR2 involved in the activation of the KATP channel by
decavanadate we constructed a range of chimeras between SUR1 and SUR2A,
based on the sequence of SUR2A, and coexpressed these chimeric SURs
with Kir6.2. The results are summarized in Fig.
4.
SUR2A containing the second nucleotide-binding domain of SUR1 (chimera
SUR21-u) or possessing transmembrane domains (TMs) 8-11 of
SUR1 (chimera SUR21-v) behaved like SUR2A. There was also no
effect of transferring TMs 12-17 (chimera SUR21-x), which
contains the tolbutamide binding site (32). When the first six TMs of SUR2A were replaced with those of SUR1 (SUR21-w), however,
the current was not activated but was instead inhibited by vanadate solution in a manner similar to Kir6.2/SUR1 (see Fig. 6B).
This suggests that the first six TMs of SUR are responsible for the different decavanadate sensitivities of SUR1 and SUR2A. As previously reported (33), exchange of this region also influenced the gating properties of the KATP channel. Like Kir6.2/SUR1, channels
comprising Kir62./SUR21-w exhibited shorter bursts and
shorter long closed states than Kir6.2/SUR2A (Fig.
5).
The data presented in this paper clearly demonstrate that
decavanadate interacts with the sulfonylurea receptor subunit of the
KATP channel and that the effect of this interaction varies with the type of SUR subunit, being largely inhibitory for channels containing SUR1 and stimulatory for channels containing SUR2A or SUR2B.
Thus, decavanadate can be used as a tool to determine which type of SUR
subunits are present in KATP channels from various tissues.
The different effects reported previously for vanadate action on native
KATP channels in skeletal muscle (24) and on cloned
Kir6.2/SUR1 channels (16) therefore result from differences in the SUR
subunit of these channels (skeletal muscle is believed to contain
SUR2A; see Ref. 6) rather than from differences in native and cloned
channels per se. The fact that Shyng et al. (16)
observed results similar to those we report when Kir6.2/SUR1 was
expressed in mammalian cells further demonstrates that the action of
vanadate is not influenced by the choice of expression system.
Our results suggest that the effects of vanadate are mediated by the
decavanadate polymer and that orthovanadate is without marked effect
either in the absence or presence of magnesium nucleotides, because the
effects of vanadate on both SUR1 and SUR2A are abolished by boiling the
solution, which destroys the decavanadate form. Furthermore, vanadate
was without a substantial effect at a concentration of 0.1 mM, where vanadate polymers are virtually absent. This is
in agreement with experiments demonstrating that orthovanadate does not
influence MgATP binding to the sulfonylurea receptor SUR1 (23). In this
respect, SUR1 differs from other members of the ABC transporter family,
such as MDR and P-glycoprotein, where nucleotide trapping by
orthovanadate has been demonstrated in binding studies (18, 19,
31).
Two pieces of evidence demonstrate that decavanadate interacts with the
SUR, rather than the Kir6.2, subunit of the KATP channel. First, decavanadate is largely ineffective when Kir6.2 Previous studies have suggested that decavanadate activates cardiac
KATP channels in a way similar to MgADP (25). In
particular, both compounds enhance the channel activity without
affecting the single-channel conductance, both are able to reactivate
rundown channels, and both require Mg2+ for their action.
Our results indicate, however, that the mechanism of action of vanadate
and MgADP is not identical, because decavanadate is able to stimulate
Kir6.2/SUR2A and Kir6.2/SUR2B channels when MgADP activation has been
abolished by mutation of the nucleotide-binding domains of SUR.
Instead, our studies suggest that the first six transmembrane domains
and/or the cytosolic loop between TMs 5 and 6 play a critical role in
channel activation either because this region contains the binding site
for decavanadate or because it is involved in transducing binding into
channel activation. It is noteworthy that the first six TM of SUR are
involved not only in the action of vanadate but also mediate the effect
of SUR on channel gating. Thus this region may be important for
transduction of vanadate binding to SUR into changes in channel gating.
*
This work was supported by the Wellcome Trust and the
British Diabetic Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.:
44-1865-272478; Fax: 44-1865-272469; E-mail:
frances.ashcroft@physiol.ox.ac.uk.
The abbreviations used are:
KATP, ATP-sensitive potassium channel;
SUR, sulfonylurea receptor;
ABC, ATP-binding cassette;
NBD, nucleotide-binding domain;
MDR, multidrug
resistance protein;
TM, transmembrane domain.
Interaction of Vanadate with the Cloned Beta Cell
KATP Channel*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-globin gene. A 36-amino acid C-terminal deletion of mouse Kir6.2 (Kir6.2
C36) was made by introduction of a
stop codon at the appropriate residue (17). Site-directed mutagenesis
of SUR was carried out by subcloning the appropriate fragments into the
pALTER vector (Promega). We use the abbreviations SUR1-KA/KM and
SUR2A-KA/KA to refer to mutation of the Walker A lysines in NBD1 and
NBD2 of SUR, to alanine (A) or methionine (M). In SUR1, this
corresponds to K719A and K1385M and in SUR2A to K707A and K1348A. A
single lysine mutation in NBD1 of SUR2B was also introduced (SUR2B-KA).
SUR chimeras containing different segments of SUR1 were constructed by
standard molecular biology techniques. The chimeras were composed of
the following segments, where the numbers refer to the sequences of
SUR1 (GenBankTM accession number L40624) or SUR2A
(GenBankTM accession number D83598) as appropriate:
SUR21-u, (1-416, SUR2A)-(424-700, SUR1)-(689-1545,
SUR2A); SUR21-v (1-1248, SUR2A)-(1285-1581, SUR1);
SUR21-w (1-307, SUR1)-(308-1545, SUR2A);
SUR21-x (1-1013, SUR2A)-(1035-1277, SUR1)-(1242-1545,
SUR2A). Synthesis of capped mRNA was carried out using the mMessage
mMachine in vitro transcription kit (Ambion). Amino acids
are indicated by the single-letter code.
C36. The final
injection volume was ~50 nl/oocyte. Isolated oocytes were maintained
in Barth's solution, and currents were studied 1-4 days after
injection (26).
110 to +100 mV. Currents were filtered at 0.2 kHz,
digitized at 0.5 kHz using a Digidata 1200 Interface, and analyzed
using pClamp software (Axon Instruments, Burlingame, CA). The data were
also stored on video tape (filter = 10 kHz), and records for
display in the figures were resampled at 20 Hz. Single-channel currents were recorded at
60 mV, filtered at 5kHz, and sampled at 20 kHz.
100 mV and
20 mV; the average of five consecutive ramps was calculated in each
solution. Currents were corrected by subtraction of the background
current measured in water-injected oocytes (~5 pA at
100 mV).
Conductance was expressed as a fraction of the mean of that obtained in
control solution before and after ATP application.
(Eq. 1)
where G and Go are the
macroscopic conductances in the presence and absence of decavanadate,
respectively, [V] is the total vanadate concentration,
EC50 is the concentration of vanadate at which the effect
is half-maximal, h is the Hill coefficient, Gmax is the maximal fractional activation of
vanadate, and L is the fraction of remaining current
unblocked by vanadate. For analysis of the inhibitory effect of
decavanadate, all values were corrected for the small inhibitory effect
of the decavanadate-free solution on Kir6.2/SUR1 currents (4%; see
Table I).
(Eq. 2)
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (25K):
[in a new window]
Fig. 1.
Effect of vanadate on different types of
KATP current. Macroscopic currents recorded from
inside-out patches excised from oocytes coinjected with mRNAs
encoding Kir6.2 and SUR2A (A, lower panel), SUR2B
(B), or SUR1 (C) or with mRNA encoding
Kir6.2
C36 (D) are shown. Currents were elicited in
response to a series of voltage ramps from
110 to +100 mV
(A, upper panel). 2 mM
Na3VO4 was added to the intracellular solution
as indicated by the bars.
Effect of vanadate species on KATP currents
C36 was expressed in the absence of SUR1, vanadate
produced only a very small (~5%) inhibition of the current (Fig.
1D and Table I). This result indicates that the SUR subunit, rather than Kir6.2, is primarily responsible for the effects of vanadate on the wild-type KATP channel, a view that is
supported by the disparate actions of vanadate on KATP
channels containing different types of SUR subunit.
C36, Kir6.2/SUR1, Kir6.2/SUR2A, or Kir6.2/SUR2B
currents. The mean conductance, expressed as a percentage of its value
in control solution, was 93%, 96%, 93%, and 95% for Kir6.2
C36,
Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B currents, respectively
(Table I). These results indicate that the effects of vanadate
solutions on channels containing SUR subunits are not mediated by the
orthovanadate complex but rather by the decavanadate form. The small
decrease in current observed for all types of KATP channel
is similar to that observed for the effect of vanadate solution on
Kir6.2
C36 currents and argues that this effect is mediated via
interaction with the Kir6.2 subunit and by vanadate species other than decavanadate.

View larger version (13K):
[in a new window]
Fig. 2.
Concentration dependence of vanadate
effects. Dose-response relation for Kir6.2/SUR2A (A) or
Kir6.2/SUR1 currents (B) and vanadate concentration is
shown. Conductance in the presence of vanadate is expressed as a
fraction of that in control solution. Each data point is the
mean of five experiments. The curves are the best fit of
Equations 1 and 2 to the data using the following parameter values for
Kir6.2/SUR2A: EC50 = 0.59 ± 0.03 mM,
h = 1.8 ± 0.2, and Gmax = 3.25 ± 0.06 and for Kir6.2/SUR1: EC50 = 0.28 ± 0.02 mM, h = 2.9 ± 0.5, and
L = 0.30 ± 0.02.

View larger version (31K):
[in a new window]
Fig. 3.
Effect of vanadate on the response of the
beta cell KATP current to MgADP. Macroscopic currents
recorded from inside-out patches excised from oocytes coinjected with
mRNAs encoding Kir6.2 and SUR1 are shown. ADP (3 or 100 µM) was added to the intracellular solution in the
absence (A) or presence (B) of decavanadate-free
vanadate solution (2 mM Na3VO4).
Currents were elicited in response to a series of voltage ramps from
110 to +100 mV.
Effect of decavanadate-free solution on the response to MgADP

View larger version (33K):
[in a new window]
Fig. 4.
Effect of vanadate solution on SUR
chimeras. The effect of vanadate solution on Kir6.2/SUR1,
Kir6.2SUR2A, and the chimeras SUR21-u, SUR21-v,
SUR21-w, and SUR21-x (see "Experimental
Procedures" for details of the chimeras) is shown. Conductance in 2 mM sodium vanadate solution is expressed as a fraction of
its value in control solution. The dotted line indicates the
control level. The numbers in brackets indicate
the number of patches.

View larger version (23K):
[in a new window]
Fig. 5.
Chimera SUR21-w possesses
gating characteristics of Kir6.2/SUR1. Single-channel currents
recorded at
60 mV from an inside-out patch excised from an oocyte
expressing Kir6.2/SUR1 (top), Kir6.2/SUR2A
(middle), and Kir6.2 plus a chimeric SUR consisting of SUR2A
with the first six transmembrane domains of SUR1 (SUR21-w;
bottom) are shown.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
C36 is expressed in the absence of SUR. Second, the effect of vanadate is
influenced by the type of SUR subunit that the KATP channel contains. In contrast to SUR2A, SUR1 is inhibited by decavanadate. It
is possible that decavanadate also exerts an inhibitory effect on SUR2A
but that this is masked by the presence of an additional stimulatory
action. The fact that decavanadate blocks a chimera consisting of SUR2A
with the first six TMs of SUR1 might be consistent with this view.
Conversely, the variable extent of inhibition of SUR1 produced by
vanadate might suggest that the ion also exerts a small stimulatory
effect on SUR1.
![]()
FOOTNOTES
Permanent address: Inst. of Molecular Physiology and Genetics, SAS
Vlárska 5, 83334 Bratislava, Slovakia.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Ashcroft, F. M.
(1988)
Annu. Rev. Neurosci.
11,
97-118[CrossRef][Medline]
[Order article via Infotrieve]
2.
Nichols, C. G.,
and Lederer, W. J.
(1991)
Am. J. Physiol.
261,
H1675-H1686 3.
Quayle, J. M.,
Nelson, M. T.,
and Standen, N. B.
(1997)
Physiol. Rev.
77,
1165-1232 4.
Aguilar-Bryan, L.,
Nichols, C. G.,
Wechsler, S. W.,
Clement, J. P.,
Boyd, A. E.,
Gonzalez, G.,
Herrera-Sosa, H.,
Nguy, K.,
Bryan, J.,
and Nelson, D. A.
(1995)
Science
268,
423-425 5.
Inagaki, N.,
Gonoi, T.,
Clement, J. P.,
Namba, N.,
Inazawa, J.,
Gonzalez, G.,
Aguilar-Bryan, L.,
Seino, S.,
and Bryan, J.
(1995)
Science
270,
1166-1169 6.
Inagaki, N.,
Gonoi, T.,
Clement, J. P., IV,
Wang, C. Z.,
Aguilar-Bryan, L.,
Bryan, J.,
and Seino, S.
(1996)
Neuron
16,
1011-1017[CrossRef][Medline]
[Order article via Infotrieve]
7.
Inagaki, N.,
Gonoi, T.,
and Seino, S.
(1997)
FEBS Lett.
409,
232-236[CrossRef][Medline]
[Order article via Infotrieve]
8.
Isomoto, S.,
Kondo, C.,
Yamada, M.,
Matsumoto, S.,
Horio, Y.,
Matsuzawa, Y.,
and Kurachi, Y.
(1996)
J. Biol. Chem.
271,
24321-24325 9.
Chutkow, W. A.,
Simon, M. C.,
Le Beau, M. M.,
and Burant, C. F.
(1996)
Diabetes
45,
1439-1445[Abstract]
10.
Clement, J. P., IV,
Kunjilwar, K.,
Gonzalez, G.,
Schwanstecher, M.,
Panten, U.,
Aguilar-Bryan, L.,
and Bryan, J.
(1997)
Neuron
18,
827-838[CrossRef][Medline]
[Order article via Infotrieve]
11.
Sakura, H.,
Ammala, C.,
Smith, P. A.,
Gribble, F. M.,
and Ashcroft, F. M.
(1995)
FEBS Lett.
377,
338-344[CrossRef][Medline]
[Order article via Infotrieve]
12.
Shyng, S. L.,
and Nichols, C. G.
(1997)
J. Gen. Physiol.
110,
655-664 13.
Higgins, C. F.
(1992)
Annu. Rev. Cell Biol.
8,
67-113[CrossRef]
14.
Gribble, F. M.,
Tucker, S. J.,
and Ashcroft, F. M.
(1997)
EMBO J.
16,
1145-1152[CrossRef][Medline]
[Order article via Infotrieve]
15.
Nichols, C. G.,
Shyng, S. L.,
Nestorowicz, A.,
Glaser, B.,
Clement, J. P., IV,
Gonzalez, G.,
Aguilar-Bryan, L.,
Permutt, M. A.,
and Bryan, J.
(1996)
Science
272,
1785-1787[Abstract]
16.
Shyng, S. L., Ferrigni, T., and Nichols, C. G. (1997)
110, 643-654
17.
Tucker, S. J.,
Gribble, F. M.,
Zhao, C.,
Trapp, S.,
and Ashcroft, F. M.
(1997)
Nature
378,
179-183
18.
Urbatsch, I. L.,
Sankaran, B.,
Weber, J.,
and Senior, A. E.
(1995)
J. Biol. Chem.
270,
19383-19390 19.
Taguchi, Y.,
Yoshida, A.,
Takada, Y.,
Komano, T.,
and Ueda, K.
(1997)
FEBS Lett.
377,
285-289
20.
Schultz, B. D.,
Bridges, R. J.,
and Frizzell, R. A.
(1996)
J. Membr. Biol.
151,
63-75[CrossRef][Medline]
[Order article via Infotrieve]
21.
Morbach, S.,
Tebbe, S.,
and Schneider, E.
(1993)
J. Biol. Chem.
268,
18617-18621 22.
Okamoto, Y.,
Sekine, T.,
Grammer, J.,
and Yount, R. G.
(1986)
Nature
324,
78-80[CrossRef][Medline]
[Order article via Infotrieve]
23.
Ueda, K.,
Inagaki, N.,
and Seino, S.
(1997)
J. Biol. Chem.
272,
22983-22986 24.
Neumcke, B.,
and Weik, R.
(1991)
Eur. Biophys. J.
19,
119-123[Medline]
[Order article via Infotrieve]
25.
Nakashima, H.,
Kakei, M.,
and Tanaka, H.
(1993)
Eur. J. Pharmacol.
233,
219-226[CrossRef][Medline]
[Order article via Infotrieve]
26.
Gribble, F. M.,
Ashfield, R.,
Ammala, C.,
and Ashcroft, F. M.
(1997)
J. Physiol.
498,
87-98
[CrossRef][Medline]
[Order article via Infotrieve] 27.
Kotowski, A.
(ed)
(1967)
Gmelins Handbook of Inorganic Chemistry, Vanadium, Part B, Division 1, System Number 48
, 8th Ed.
, pp. 132-157, Verlag Chemie
28.
Lobert, S.,
Isern, N.,
Hennington, B. S.,
and Correia, J. J.
(1994)
Biochemistry
33,
6244-6252[CrossRef][Medline]
[Order article via Infotrieve]
29.
Senior, A. E.,
and Bhagat, S.
(1998)
Biochemistry
37,
831-836[CrossRef][Medline]
[Order article via Infotrieve]
30.
Chasteen, N. D.
(1983)
Struct. Bonding
53,
105-138
31.
Hrycyna, C. A.,
Ramchandra, M.,
Ambudkar, S. V.,
Ko, Y. H.,
Pedersen, P. L.,
Pastan, I.,
and Gottesman, M. M.
(1998)
J. Biol. Chem.
273,
16631-16634 32.
Ashfield, R.,
Gribble, F. M.,
Ashcroft, S. J. H.,
and Ashcroft, F. M.
(1999)
Diabetes
48,
1341-1347[Abstract]
33.
Babenko, A. P.,
Gonzalez, G.,
and Bryan, J.
(1999)
J. Biol. Chem.
274,
11587-11592
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
L. Csanady and V. Adam-Vizi Antagonistic Regulation of Native Ca2+- and ATP-sensitive Cation Channels in Brain Capillaries by Nucleotides and Decavanadate J. Gen. Physiol., June 1, 2004; 123(6): 743 - 757. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Pezza, M. A. Villarreal, G. G. Montich, and C. E. Argarana Vanadate inhibits the ATPase activity and DNA binding capability of bacterial MutS. A structural model for the vanadate-MutS interaction at the Walker A motif Nucleic Acids Res., November 1, 2002; 30(21): 4700 - 4708. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matsuo, N. Kioka, T. Amachi, and K. Ueda ATP Binding Properties of the Nucleotide-binding Folds of SUR1 J. Biol. Chem., December 24, 1999; 274(52): 37479 - 37482. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matsuo, K. Tanabe, N. Kioka, T. Amachi, and K. Ueda Different Binding Properties and Affinities for ATP and ADP among Sulfonylurea Receptor Subtypes, SUR1, SUR2A, and SUR2B J. Biol. Chem., September 8, 2000; 275(37): 28757 - 28763. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-K. Song and F. M. Ashcroft ATP Modulation of ATP-sensitive Potassium Channel ATP Sensitivity Varies with the Type of SUR Subunit J. Biol. Chem., March 2, 2001; 276(10): 7143 - 7149. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |